Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN (IPN)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 09/25 01:11:47 pm
143.9 EUR   +0.56%
11:25aIPSEN : receives positive CHMP opinion for Cabometyx for the second-..
AQ
09/24IPSEN : The underlying trend is to the upside
09/21IPSEN : relocating German affiliate to Munich
PU
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Ipsen : supports awareness of Neuroendocrine Tumors (NET) and the NET Cancer Day on November 10, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 04:24pm CEST

NET Cancer Day on the 10th of November 2017, is an annual event dedicated to raising awareness of a rare cancer, neuroendocrine tumors (NET).


NET Cancer Day, a global initiative of the International Neuroendocrine Cancer Alliance (INCA) and its members, aims to inform and raise awareness of this often undetected and rare disease amongst the general public and medical institutions with the ultimate goal of providing patients with improved diagnosis and care as they live with NET.
Neuroendocrine tumors: An unusual type of cancer

For more information on NET disease and Cancer Day please visit:
International Neuroendocrine Cancer Alliance
Living with NETs

Livingwithnets.com Website and its contents are intended for an international audience, excluding the United States, Canada and France.

Ipsen SA published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 15:23:04 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IPSEN
11:25aIPSEN : receives positive CHMP opinion for Cabometyx for the second-line treatme..
AQ
09/24IPSEN : Receives Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Seco..
AQ
09/21IPSEN : relocating German affiliate to Munich
PU
09/04IPSEN : Share buyback
CO
08/31IPSEN : Monthly statement on outstanding equity shares and voting rights
CO
08/31IPSEN : Monthly statement on outstanding equity shares and voting rights
CO
08/28IPSEN : Monthly statement on outstanding equity shares and voting rights
CO
08/21IPSEN : Share buyback
CO
08/10Merrimack Reports Second Quarter 2018 Financial Results
AQ
08/07IPSEN : Share buyback
CO
More news
News from SeekingAlpha
09/21Exelixis? partner Ipsen announces positive CHMP opinion for CABOMETYX tablets 
07/29Ipsen S.A. ADR (IPSEY) CEO David Meek on Q2 2018 Results - Earnings Call Tran.. 
07/26Ipsen S.A. ADR 2018 Q2 - Results - Earnings Call Slides 
07/26Ipsen S.A. ADR reports 1H results 
07/19Ipsen and Biolabs to open new innovation center in Cambridge (U.S.) 
Financials (€)
Sales 2018 2 288 M
EBIT 2018 640 M
Net income 2018 433 M
Debt 2018 259 M
Yield 2018 0,76%
P/E ratio 2018 27,20
P/E ratio 2019 22,31
EV / Sales 2018 5,35x
EV / Sales 2019 4,65x
Capitalization 11 991 M
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 152 €
Spread / Average Target 6,0%
EPS Revisions
Managers
NameTitle
David D. Meek Chief Executive Officer & Director
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Alexandre P. LeBeaut Chief Scientific Officer
Sotirios G. Stergiopoulos Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN43.72%14 081
JOHNSON & JOHNSON2.26%376 847
PFIZER21.29%257 522
NOVARTIS-0.63%217 697
ROCHE HOLDING LTD.-5.48%209 212
MERCK AND COMPANY26.36%188 241